§ Structure design and procedure:
§ Structure design and procedure:
• The cost analysis was performed prospectively based on data from a multicenter study.
Randomization was not possible due to availability of equipment.
• The study was conducted in accordance with the ethical principles for medical research involving human subjects developed in the Declaration of Helsinki by the World Medical Association (WMA). § Patients:
• Patients treated for epidermoid or undifferentiated nasopharyngeal (UCNT) carcinoma, epidemoid carcinoma of oropharynx and oral cavity (T1-T4, M0). Age ≥ 18 years. § Cost assessment:
• Cost calculations were based strictly on a micro-costing approach according to the hospitals' perspective. Only resources which are likely to vary between the strategies being compared were considered.
• Resources were collected prospectively from the treatment planning process until the last radiation session of the delivery system. Times required in terms of personnel and duration of radiation room occupation were assessed for each patient by direct measurement using a chronometer.
In radiotherapy, helical tomotherapy is a very important technological advance in terms of modularity and security for complex radiations. Dynamic Arc Therapy theoretically offers a similar benefit with potentially reduced processing time. Both are currently limited in France by investment costs and personnel mobilized by the implementation of these techniques. Medico economic valuation is a necessary step to the dissemination theses innovations. This is why a cost analysis investigating TomoTherapy® (Accuray), Elekta Volumetric-modulated Arc Therapy (VMAT®) and Varian RapidArc® was conducted in patients with head and neck cancer. § As micro-costing made by direct measurement using a chronometer requires significant resources, many costs have not been taken into account in this study (e.g., breaks, meetings, productivity losses (technical problems/organizational constraints), absenteeism, costs of administrative personnel, medical expenses, costs of logistics and general management, costs of transportation, indirect costs). Moreover, only resources which are likely to vary between the strategies being compared were considered. Therefore, any comparison with the pricing system (Groupes Homogènes de Séjours) should be made. § Absence of randomization, learning effects and variation in clinical practices amongst centers) could affect the strenght of the study. § Comparison of VMAT® with other technics remains not possible due to sample size (n=8) and learning effect (e.g. duration session of VMAT®) could be associated with a learning effect. § Costs of TomoTherapy® appeared more expensive than RapidArc® mainly due to a higher price of accelerator, higher costs of maintenance, and longer duration sessions. § To our knowledge, this is the first study highlighting costs incurred by different Intensity-Modulated Arc Therapy (IMAT) modalities in this setting. Cost-effectiveness studies should be conducted to shed further light on which strategy to focus on. This study was funded by the National Cancer Institute (INCa). • For irradiation, the mean over cost of TomoTherapy® reached €1,794 per patient compared to Varian RapidArc®. Estimated costs of VMAT were not generalizable because of they were determined from a small sample size (n=8). § Patients:
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• • One patient was erroneously included. Six patients included were not treated for withdrawal of consent, investigator's decision, progressive disease and treatment non feasible. Among the 174 remaining patients, 173 economic questionnaires could be used.
Study limitations and conclusions § Cost assessment (followed):
• Unit prices and costs were given by the accounting departments from the participating centres in the study. All costs were expressed in year 2013 Euro, inclusive of tax.
• The mean yearly wage costs were calculated based on what a staff member would earn after 10 years of professional experience. The lifetime period was 5 years for the Treatment planning system and 10 years for the accelerators respectively. The annual operating time of the accelerators was estimated to amount to 2600 hours, except for TomoTherapy® where we considered a one-day by month interruption time for maintenance. § Statistical analysis:
• The uncertainty surrounding costs was assessed by one way analyses (Tornado Diagrams) and probabilistic sensibility analyses using a non-parametric bootstrap method. 1,000 simulated bootstrap samples were generated by independent draws for TomoTherapy® and Dynamic Arc Therapy (RapidArc® and VMAT®). 95% confidence intervals of mean costs are reported.
• All analyses were performed using SAS (SAS Institute, Cary, NC) and STATA® software. • The annual operating time of the accelerators played a major role in irradiation cost (Tornado diagram). • Sessions duration on day 1 was 24 minutes in average (SD:6) with TomoTherapy®, 17 minutes (SD:7) with RapidArc®, and 28 min (SD: 17) with VMAT®. The average duration slightly decreased with the session number (i.e. the duration was 21 minutes (SD: 6), 12 minutes (SD: 4) and 18 minutes (SD: 18) respectively between day 4 to the end of irradiation).
(1) Kruskal-Wallis test; (2) Fisher Exact test; (3) Missing data n=2
